Background
Antibiotics like Tigecycline are vital for combating bacterial infections, but their intravenous delivery restricts usage to healthcare facilities, limiting options for patients outside such settings. The rise of multidrug-resistant respiratory infections, like those caused by S. maltophilia, necessitates innovative delivery approaches. Current intravenous methods face degradation issues, hampering outpatient treatment. Therefore, alternative delivery methods are sought to ensure stability and versatility in treatment environments.
Technology description
A study explores an inhaled dry powder form of Tigecycline, traditionally administered intravenously. This innovation allows treatment outside hospitals for drug-resistant respiratory infections. Trials show high aerosolization efficiency and stability of micronized Tigecycline, ensuring effectiveness against bacterial cultures. This offers promising treatment outcomes for lung infections through pulmonary delivery.
Benefits
- Non-invasive, effective treatment option against multidrug-resistant bacteria
- Suitable for outpatient use
- Stability across varying conditions
- High aerosolization efficiency ensures practicality and efficacy in pulmonary delivery.
Commercial applications
- Outpatient treatment for multidrug-resistant respiratory infections
- Home-based care for bacterial pneumonia patients
- Emergency responses for respiratory outbreaks
- Military and field hospital use where intravenous administration isn't feasible
About the inventor
Dr. Smyth, an accomplished researcher, has developed innovative drug delivery devices applicable across various medical sectors, including respiratory systems. With over 150 publications and numerous patents, his work significantly impacts medical advancements.
Opportunity
The University of Texas at Austin is seeking a commercial license to this technology.
